ENZO BIOCHEM INC. overview

The law firm of Federman & Sherwood has initiated an investigation into Enzo Biochem with respect to their recent data breach. On May 30, 2023, Enzo Biochem notified 2.47 million patients that the company experienced a data breach after an unauthorized party accessed sensitive consumer data entrusted to the company. According to Enzo Biochem, they determined that information stored on their servers may have been subject to unauthorized access on April 6, 2023. Enzo Biochem determined that the...

SHAREHOLDER ALERT: Weiss Law Investigates Enzo Biochem, Inc. PR Newswire NEW YORK, May 2, 2023 NEW YORK , May 2, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Enzo Biochem, Inc. ("Enzo Biochem" or the "Company") (NYSE: ENZ) in connection with its acquisition by Laboratory Corporation of America Holdings (NYSE: LH) ("Labcorp"). The transaction value is approximately $146 million . If you own Enzo...

Bradley L. Radoff, who together with his affiliates holds approximately 7.5% of the outstanding common shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today issued the following open letter to the independent members of the Company’s Board of Directors (the “Board”): Independent Directors, I am writing to address your seemingly hollow and tone-deaf response to my October 19 th letter to recently-appointed directors Dr. Mary Tagliaferri and Dr. Ian B. Walters. As you...

Bradley L. Radoff, who together with his affiliates holds approximately 7.2% of the outstanding common shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today issued the following open letter to Dr. Mary Tagliaferri and Dr. Ian B. Walters, who joined the Company’s Board of Directors (the “Board”) in November 2020: Dr. Tagliaferri and Dr. Walters, As you likely know, I am one of Enzo’s largest shareholders and have recently nominated two highly-qualified, independent...

...

Roumell Announces Preliminary Annual Meeting Results for Enzo Biochem, Inc. At a Minimum, Chairman and CEO, Dr. Elazar Rabbani, Must Tender His Resignation from the Board According to Roumell's Initial Tabulations Had the Board Honored Roumell's Nominations and GREEN Proxy Card, Shareholders Would Have Achieved Additional Board and Business Changes Roumell Demands Meeting with the Non-Executive Directors to Accept Dr. Rabbani's Resignation Which Should be Immediately Effective PR Newswire CHEVY...

Roumell Asset Management Files Definitive Proxy Statement and Sends Letter to Enzo Biochem Shareholders Urges Shareholders to Support Two Highly Qualified Director Nominees by Voting the GREEN Proxy Card Believes Enzo Biochem should delay its Annual Meeting PR Newswire CHEVY CHASE, Md., Dec. 24, 2020 CHEVY CHASE, Md. , Dec. 24, 2020 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock of Enzo Biochem, Inc.(NYSE: ENZ) ("Enzo" or...